Kite and HiFiBio Signs a Research & License Agreement for Neoantigen-Reactive T Cell Receptors (TCRs)

 Kite and HiFiBio Signs a Research & License Agreement for Neoantigen-Reactive T Cell Receptors (TCRs)

Kite and HiFiBio Signs a Research & License Agreement for Neoantigen-Reactive T Cell Receptors (TCRs)

Shots:

  • The collaboration is focused on developing technology for neoantigen-reactive T cell receptors (TCRs) to treat cancers, including solid tumor
  • HiFiBio to get an upfront $10M with additional milestones payments and Kite will hold an exclusive option to license HiFiBiO’s single cell technology platform
  • HiFiBio Therapeutics is focused on activating human immune system to fight diseases. It is using its single-cell profiling technology to treat cancer and autoimmune disorder

Click here to read full press release/ article | Ref: Gilead | Image: HifiBio

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post